247 related articles for article (PubMed ID: 32571879)
1. Comparative study of the stabilities of synthetic
Raimondi S; Mangione PP; Verona G; Canetti D; Nocerino P; Marchese L; Piccarducci R; Mondani V; Faravelli G; Taylor GW; Gillmore JD; Corazza A; Pepys MB; Giorgetti S; Bellotti V
J Biol Chem; 2020 Aug; 295(33):11379-11387. PubMed ID: 32571879
[TBL] [Abstract][Full Text] [Related]
2. The importance of a gatekeeper residue on the aggregation of transthyretin: implications for transthyretin-related amyloidoses.
Sant'Anna R; Braga C; Varejão N; Pimenta KM; Graña-Montes R; Alves A; Cortines J; Cordeiro Y; Ventura S; Foguel D
J Biol Chem; 2014 Oct; 289(41):28324-37. PubMed ID: 25086037
[TBL] [Abstract][Full Text] [Related]
3. Amyloid seeding of transthyretin by ex vivo cardiac fibrils and its inhibition.
Saelices L; Chung K; Lee JH; Cohn W; Whitelegge JP; Benson MD; Eisenberg DS
Proc Natl Acad Sci U S A; 2018 Jul; 115(29):E6741-E6750. PubMed ID: 29954863
[TBL] [Abstract][Full Text] [Related]
4. Uncovering the Mechanism of Aggregation of Human Transthyretin.
Saelices L; Johnson LM; Liang WY; Sawaya MR; Cascio D; Ruchala P; Whitelegge J; Jiang L; Riek R; Eisenberg DS
J Biol Chem; 2015 Nov; 290(48):28932-43. PubMed ID: 26459562
[TBL] [Abstract][Full Text] [Related]
5. Dissociation of amyloid fibrils of alpha-synuclein and transthyretin by pressure reveals their reversible nature and the formation of water-excluded cavities.
Foguel D; Suarez MC; Ferrão-Gonzales AD; Porto TC; Palmieri L; Einsiedler CM; Andrade LR; Lashuel HA; Lansbury PT; Kelly JW; Silva JL
Proc Natl Acad Sci U S A; 2003 Aug; 100(17):9831-6. PubMed ID: 12900507
[TBL] [Abstract][Full Text] [Related]
6. Wild-type transthyretin significantly contributes to the formation of amyloid fibrils in familial amyloid polyneuropathy patients with amyloidogenic transthyretin Val30Met.
Tsuchiya-Suzuki A; Yazaki M; Kametani F; Sekijima Y; Ikeda S
Hum Pathol; 2011 Feb; 42(2):236-43. PubMed ID: 21056899
[TBL] [Abstract][Full Text] [Related]
7. In vitro modelling of familial amyloidotic polyneuropathy allows quantitative detection of transthyretin amyloid fibril-like structures in hepatic derivatives of patient-specific induced pluripotent stem cells.
Hoepfner J; Kleinsorge M; Papp O; Alfken S; Heiringhoff R; Pich A; Sauer V; Zibert A; Göhring G; Schmidt H; Sgodda M; Cantz T
Biol Chem; 2017 Jul; 398(8):939-954. PubMed ID: 28051995
[TBL] [Abstract][Full Text] [Related]
8. Dissecting the structure, thermodynamic stability, and aggregation properties of the A25T transthyretin (A25T-TTR) variant involved in leptomeningeal amyloidosis: identifying protein partners that co-aggregate during A25T-TTR fibrillogenesis in cerebrospinal fluid.
Azevedo EP; Pereira HM; Garratt RC; Kelly JW; Foguel D; Palhano FL
Biochemistry; 2011 Dec; 50(51):11070-83. PubMed ID: 22091638
[TBL] [Abstract][Full Text] [Related]
9. Tolcapone, a potent aggregation inhibitor for the treatment of familial leptomeningeal amyloidosis.
Pinheiro F; Varejão N; Esperante S; Santos J; Velázquez-Campoy A; Reverter D; Pallarès I; Ventura S
FEBS J; 2021 Jan; 288(1):310-324. PubMed ID: 32324953
[TBL] [Abstract][Full Text] [Related]
10. Disulfide-bond formation in the transthyretin mutant Y114C prevents amyloid fibril formation in vivo and in vitro.
Eneqvist T; Olofsson A; Ando Y; Miyakawa T; Katsuragi S; Jass J; Lundgren E; Sauer-Eriksson AE
Biochemistry; 2002 Nov; 41(44):13143-51. PubMed ID: 12403615
[TBL] [Abstract][Full Text] [Related]
11. Disease-associated mutations impacting BC-loop flexibility trigger long-range transthyretin tetramer destabilization and aggregation.
Esperante SA; Varejāo N; Pinheiro F; Sant'Anna R; Luque-Ortega JR; Alfonso C; Sora V; Papaleo E; Rivas G; Reverter D; Ventura S
J Biol Chem; 2021 Sep; 297(3):101039. PubMed ID: 34343569
[TBL] [Abstract][Full Text] [Related]
12. A pair of peptides inhibits seeding of the hormone transporter transthyretin into amyloid fibrils.
Saelices L; Nguyen BA; Chung K; Wang Y; Ortega A; Lee JH; Coelho T; Bijzet J; Benson MD; Eisenberg DS
J Biol Chem; 2019 Apr; 294(15):6130-6141. PubMed ID: 30733338
[TBL] [Abstract][Full Text] [Related]
13. Familial amyloidotic polyneuropathy: protein aggregation in the peripheral nervous system.
João Saraiva M; Mendes Sousa M; Cardoso I; Fernandes R
J Mol Neurosci; 2004; 23(1-2):35-40. PubMed ID: 15126690
[TBL] [Abstract][Full Text] [Related]
14. Transthyretin Misfolding, A Fatal Structural Pathogenesis Mechanism.
Si JB; Kim B; Kim JH
Int J Mol Sci; 2021 Apr; 22(9):. PubMed ID: 33922648
[TBL] [Abstract][Full Text] [Related]
15. Pathological, biochemical, and biophysical characteristics of the transthyretin variant Y114H (p.Y134H) explain its very mild clinical phenotype.
Sekijima Y; Campos RI; Hammarström P; Nilsson KP; Yoshinaga T; Nagamatsu K; Yazaki M; Kametani F; Ikeda S
J Peripher Nerv Syst; 2015 Dec; 20(4):372-9. PubMed ID: 26306725
[TBL] [Abstract][Full Text] [Related]
16. Transthyretin fibrillogenesis entails the assembly of monomers: a molecular model for in vitro assembled transthyretin amyloid-like fibrils.
Cardoso I; Goldsbury CS; Müller SA; Olivieri V; Wirtz S; Damas AM; Aebi U; Saraiva MJ
J Mol Biol; 2002 Apr; 317(5):683-95. PubMed ID: 11955017
[TBL] [Abstract][Full Text] [Related]
17. Structural distribution of mutations associated with familial amyloidotic polyneuropathy in human transthyretin.
Eneqvist T; Sauer-Eriksson AE
Amyloid; 2001 Sep; 8(3):149-68. PubMed ID: 11676293
[TBL] [Abstract][Full Text] [Related]
18. Unusual duplication mutation in a surface loop of human transthyretin leads to an aggressive drug-resistant amyloid disease.
Klimtchuk ES; Prokaeva T; Frame NM; Abdullahi HA; Spencer B; Dasari S; Cui H; Berk JL; Kurtin PJ; Connors LH; Gursky O
Proc Natl Acad Sci U S A; 2018 Jul; 115(28):E6428-E6436. PubMed ID: 29941560
[TBL] [Abstract][Full Text] [Related]
19. Effect of nitric oxide in amyloid fibril formation on transthyretin-related amyloidosis.
Saito S; Ando Y; Nakamura M; Ueda M; Kim J; Ishima Y; Akaike T; Otagiri M
Biochemistry; 2005 Aug; 44(33):11122-9. PubMed ID: 16101296
[TBL] [Abstract][Full Text] [Related]
20. A cell-based high-throughput screening method to directly examine transthyretin amyloid fibril formation at neutral pH.
Ueda M; Okada M; Mizuguchi M; Kluve-Beckerman B; Kanenawa K; Isoguchi A; Misumi Y; Tasaki M; Ueda A; Kanai A; Sasaki R; Masuda T; Inoue Y; Nomura T; Shinriki S; Shuto T; Kai H; Yamashita T; Matsui H; Benson MD; Ando Y
J Biol Chem; 2019 Jul; 294(29):11259-11275. PubMed ID: 31167790
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
